|
1
|
Katayama R, Khan TM, Benes C, Lifshits E,
Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA and Shaw
AT: Therapeutic strategies to overcome crizotinib resistance in
non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Katayama R, Shaw AT, Khan TM,
Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT,
Benes C, et al: Mechanisms of acquired crizotinib resistance in
ALK-rearranged lung cancers. Sci Transl Med. 4:120ra172012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sasaki T, Koivunen J, Ogino A, Yanagita M,
Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, et al: A
novel ALK secondary mutation and EGFR signaling cause resistance to
ALK kinase inhibitors. Cancer Res. 71:6051–6060. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lovly CM, McDonald NT, Chen H,
Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang
L, et al: Rationale for co-targeting IGF-1R and ALK in ALK
fusion-positive lung cancer. Nat Med. 20:1027–1034. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fujita S, Masago K, Katakami N and Yatabe
Y: Transformation to SCLC after treatment with the ALK inhibitor
alectinib. J Thorac Oncol. 11:e67–e72. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ou SI, Lee TK, Young L, Fernandez-Rocha
MY, Pavlick D, Schrock AB, Zhu VW, Milliken J, Ali SM and Gitlitz
BJ: Dual occurrence of ALK G1202R solvent front mutation and small
cell lung cancer transformation as resistance mechanisms to second
generation ALK inhibitors without prior exposure to crizotinib.
Pitfall of solely relying on liquid re-biopsy? Lung Cancer.
106:110–114. 2017.PubMed/NCBI
|
|
7
|
Stieber P, Dienemann H, Schalhorn A,
Schmitt UM, Reinmiedl J, Hofmann K and Yamaguchi K:
Pro-gastrin-releasing peptide (ProGRP)-a useful marker in small
cell lung carcinomas. Anticancer Res. 19:2673–2678. 1999.PubMed/NCBI
|
|
8
|
Gainor JF, Dardaei L, Yoda S, Friboulet L,
Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K,
Singh M, et al: Molecular mechanisms of resistance to first- and
second-generation ALK inhibitors in ALK-rearranged lung cancer.
Cancer Discov. 6:1118–1133. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Paweletz CP, Sacher AG, Raymond CK, Alden
RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English
JM, et al: Bias-corrected targeted next-generation sequencing for
rapid, multiplexed detection of actionable alterations in cell-free
DNA from advanced lung cancer patients. Clin Cancer Res.
22:915–922. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lodrini M, Sprüssel A, Astrahantseff K,
Tiburtius D, Konschak R, Lode HN, Fischer M, Keilholz U, Eggert A
and Deubzer HE: Using droplet digital PCR to analyze MYCN and ALK
copy number in plasma from patients with neuroblastoma. Oncotarget.
8:85234–85251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnson AC, Dô P, Richard N, Dubos C,
Michels JJ, Bonneau J and Gervais R: Identification of I1171N
resistance mutation in ALK-positive non-small-cell lung cancer
tumor sample and circulating tumor DNA. Lung Cancer. 99:38–40.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bordi P, Tiseo M, Rofi E, Petrini I,
Restante G, Danesi R and Del Re M: Detection of ALK and KRAS
mutations in circulating tumor DNA of patients with advanced
ALK-positive NSCLC with disease progression during crizotinib
treatment. Clin Lung Cancer. 18:692–697. 2017. View Article : Google Scholar : PubMed/NCBI
|
